Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Campus Biomedico University, Italy
Researchers from Italy and Netherlands describe findings in lung cancer studies
July 4th, 2006
Lung cancer research advances have been reported from Italy and Netherlands. Study 1: Elderly non-small cell lung cancer (NSCLC) patients could be treated by carboplatin and paclitaxel as first line chemotherapy. According to recent research from Italy, "Lung cancer is the leading cause of tumour-related deaths in the elderly population but the optimal management of advanced NSCLC in older patients has not been defined to date. The present phase II study was planned to evaluate the efficacy and toxicity of the combination of carboplatin and paclitaxel in elderly patients with advanced NSCLC." "Patients (>70 years old) who had...
Source: Pharma Law Weekly (2006-07-04)
|
